Detalhe da pesquisa
1.
Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial.
Blood
; 141(11): 1265-1276, 2023 03 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36265087
2.
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need.
Blood
; 141(6): 567-578, 2023 02 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36399715
3.
Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001.
Br J Haematol
; 204(3): 877-886, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37952982
4.
Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.
Blood
; 140(15): 1674-1685, 2022 10 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35960871
5.
Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status.
Blood
; 139(14): 2145-2155, 2022 04 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34995344
6.
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.
N Engl J Med
; 383(26): 2526-2537, 2020 12 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-33369355
7.
BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells.
Blood
; 137(6): 812-825, 2021 02 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32911532
8.
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party.
Blood
; 138(26): 2753-2767, 2021 12 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-34724563
9.
A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia.
Haematologica
; 108(3): 705-716, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36226495
10.
A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia.
Hematol Oncol
; 41(4): 743-752, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37086447
11.
Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panel.
Am J Hematol
; 98(12): 1847-1855, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37671649
12.
Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study.
Blood
; 136(6): 674-683, 2020 08 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32285126
13.
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.
Blood
; 135(7): 463-471, 2020 02 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31841594
14.
The epichaperome is an integrated chaperome network that facilitates tumour survival.
Nature
; 538(7625): 397-401, 2016 Oct 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-27706135
15.
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
N Engl J Med
; 378(25): 2386-2398, 2018 Jun 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-29860938
16.
Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib.
Blood
; 133(7): 676-687, 2019 02 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-30510081
17.
The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types.
Cancer
; 126(14): 3192-3201, 2020 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32401342
18.
Low participation rates and disparities in participation in interventional clinical trials for myelodysplastic syndromes.
Cancer
; 126(21): 4735-4743, 2020 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32767690
19.
Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre setting.
Br J Haematol
; 190(6): 891-900, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32239670
20.
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.
Blood
; 131(12): 1275-1291, 2018 03 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-29330221